Arcutis Biotherapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ARQT Nasdaq 2836 www.arcutis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arcutis Biotherapeutics, Inc.

Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability - Aug 6th, 2026 6:50 am
Arcutis Biotherapeutics Inc (ARQT) (Q2 2026) Earnings Call Highlights: Revenue Surges 59% and ... - Aug 5th, 2026 11:08 pm
Arcutis Biotherapeutics Q2 Earnings Call Highlights - Aug 5th, 2026 4:03 pm
Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates - Aug 5th, 2026 3:10 pm
Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update - Aug 5th, 2026 2:00 pm
Viatris Gears Up to Report Q2 Earnings: What's in the Cards? - Aug 4th, 2026 9:37 am
Outlook Therapeutics to Report Q3 Earnings: What's in the Cards? - Aug 3rd, 2026 8:58 am
Arcutis Biotherapeutics (ARQT) Stock Trades At A Discount To Sales But Fair Value Looks Tight - Jul 31st, 2026 9:10 am
Arcutis Biotherapeutics (ARQT) Heads Into Earnings With Its ZORYVE Story Still Shaping Valuation - Jul 31st, 2026 12:08 am
Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline - Jul 30th, 2026 8:00 am
Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Jul 29th, 2026 8:00 am
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 25.79%: Read This Before Placing a Bet - Jul 21st, 2026 7:55 am
Arcutis Expands Board of Directors with Appointment of Chris Peetz - Jul 16th, 2026 7:00 am
Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 - Jul 15th, 2026 2:00 pm
Attovia Therapeutics Appoints John W. Smither to Board of Directors - Jul 15th, 2026 6:30 am
Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatment - Jul 9th, 2026 11:37 am
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months - Jul 8th, 2026 6:00 am
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? - Jul 3rd, 2026 6:57 am
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jul 2nd, 2026 2:00 pm
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications - Jun 30th, 2026 7:15 am